Abstract
n May 2016, US FDA advised to restrict fluoroquinolones use in patients with acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. The reason for this decision was the new safety data obtained during the pharmacovigilance in the USA – Fluoroquinolone-Associated Disability (FQAD). This article discusses issues of fluoroquinolone safety and regulatory measures to prevent a risk for serious adverse drug reactions in the administration of this antibiotic class. A special attention is paid to FQAD and its clinical significance in terms of rational fluoroquinolone use.
RUDN University, Moscow, Russia
RUDN University, Moscow, Russia
-
1.
Douros A., Grabowski K., Stahlmann R. Safety issues and drug-drug interactions with commonly used quinolones. USExpert Opin Drug Metab Toxicol. 2015;11(1):25-39.
-
2.
Stahlmann R., Lode H.M. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 2013;12(4):497-505.
-
3.
Rouveix B. Antibiotic safety assessment. Int J Antimicrob Agents. 2003;21(3):215-221.
-
4.
Ittner K.P. Gatifloxacin and dysglycemia in older adults. N Engl J Med. 2006;354(25):2725-2726.
-
5.
Stahlmann R., Lode H. Toxicity of quinolones. Drugs. 1999;58(Suppl 2): 37-42.
-
6.
Yakovlev S.V. Place of the fluoroquinolones in the treatment of bacterial infections. Lechashhij vrach. 2008;(2):59-63. Russian.
-
7.
Stahlmann R., Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209.
-
8.
Liu H.H. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33:353-369.
-
9.
Ho C.C., Chen Y.C., Hu F.C., et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 2009;48:1526-1533.
-
10.
FDA Briefing Document. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 5, 2015 г. The Benefits and Risks of Systemic Fluoroquinolone Antibacterial Drugs for the Treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients Who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD),and Uncomplicated Urinary Tract Infections (uUTI). Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiInfectiveDrugsAdvisoryCommittee/UCM467383.pdf.
-
11.
FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [05-12-2016].
-
12.
IMS Health National Sales Perspective (NSP), Y2014. Source File: NSP_2015-896 FQ AC 2014.
-
13.
Nambiar S., FDA Introductory Remarks. Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee November 5, 2015 Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/UCM472655.pdf
-
14.
European Medicines Agency (EMA) Guideline on good pharmacovilance (GVP). Management and reporting of adverse reactions to medicinal products. 2013.
-
15.
Tillotson G.S. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Lancet Infect Dis. 2016;16(3):e11-12.
-
16.
Vance M. New FDA restrictions for fluoroquinolones. Clinical Rx Forum. 2016;4(4):1-2.